Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
Kathrin Strasser-WeipplPaul E Goss

Abstract

In resource-constrained environments many patients with human epidermal growth factor receptor 2 (HER2)+ early breast cancer are currently not offered adjuvant anti-HER2 therapy. For patients who might be able to receive the tyrosine kinase inhibitor (TKI) lapatinib (e.g. after patent expiration), it is important to identify subgroups of patients for whom anti-HER2 TKI therapy could be beneficial. To do this, we used data from 2489 patients with centrally confirmed HER2+ disease enrolled in the adjuvant Tykerb Evaluation After Chemotherapy (TEACH) trial, investigating the effect of lapatinib in patients with HER2+ early breast cancer not treated with trastuzumab. We performed subgroup analyses and number-needed-to-treat (NNT) calculations using patient and tumour associated predictors. Hormone receptor negative (HR-) patients on lapatinib had a significantly prolonged disease-free survival (DFS) compared to HR- patients on placebo (hazard ratio 0.64, P=0.003). For patients with HR- disease, starting treatment with lapatinib ≤1 year from diagnosis improved DFS by 12.1% [2.1-22.1] at 2 years and 15.7% [4.1-27.2] at 5 years. Depending on lymph node status and time since diagnosis the NNT for recurrence (at 5 years) was between 5.9...Continue Reading

References

Jun 30, 1988·The New England Journal of Medicine·A LaupacisR S Roberts
Jan 1, 1997·Stem Cells·D M Reese, D J Slamon
Jan 17, 2003·Journal of the National Cancer Institute·Gottfried KonecnyDennis J Slamon
Sep 18, 2003·Journal of the National Cancer Institute·Frédérique SpyratosKamel Hacène
Oct 21, 2005·The New England Journal of Medicine·Martine J Piccart-GebhartUNKNOWN Herceptin Adjuvant (HERA) Trial Study Team
Oct 21, 2005·The New England Journal of Medicine·Edward H RomondNorman Wolmark
Dec 29, 2006·The New England Journal of Medicine·Charles E GeyerDavid Cameron
Feb 26, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M UntchUNKNOWN HERA Study Team
Aug 1, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·F PeintingerW F Symmans
Nov 4, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Heikki JoensuuPirkko-Liisa Kellokumpu-Lehtinen
Nov 26, 2010·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Rohit BhargavaGretchen M Ahrendt
Jun 29, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A GoldhirschUNKNOWN Panel members
Jul 20, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Edith A PerezNorman Wolmark
Oct 14, 2011·The New England Journal of Medicine·Dennis SlamonUNKNOWN Breast Cancer International Research Group
Nov 2, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Edith A PerezRobert B Jenkins
Mar 3, 2012·The Lancet Oncology·Brittany L LeePaul E Goss

❮ Previous
Next ❯

Citations

Nov 25, 2016·Expert Review of Anticancer Therapy·Matteo LambertiniEvandro de Azambuja
Aug 10, 2017·Oncology Letters·Fuqian YangNana Zhao

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Annals of Oncology : Official Journal of the European Society for Medical Oncology
Michael UntchHERA Study Team
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Edith A PerezRobert B Jenkins
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Mitch DowsettBrian Leyland-Jones
© 2021 Meta ULC. All rights reserved